Rectal Cancer Therapeutics 2018: Pipeline Analysis, Clinical Trials & Results, Patents, Designations, Collaborations and Other Developments - ResearchAndMarkets.com

DUBLIN--()--The "Rectal Cancer Therapeutics - Pipeline Analysis 2018, Clinical Trials & Results, Patents, Designations, Collaborations, and Other Developments" report has been added to ResearchAndMarkets.com's offering.

According to the research findings, most of the drug candidates for the treatment of rectal cancer are being developed to be administered by the intravenous and the oral route.

It has been observed that most of the therapeutics that are being developed for acting on the specific target, and interventional studies including targeted therapeutics for the treatment of rectal cancer, have showed positive efficacy in the clinical as well as Pre-Clinical stage of development. An example of such therapy includes, Ziv-aflibercept, a fusion protein, under the Phase II stage of development by Sanofi S.A. for the treatment of rectal cancer. Ziv-aflibercept has been approved by USFDA for use in combination with 5-fluorouracil, leucovorin, and irinotecan in patients with metastatic colorectal cancer and rectal cancer.

It has been observed that, rise in geriatric population and increasing incidence of rectal cancer has been driving the growth of the rectal cancer pipeline. According to the National Cancer Institute, in 2017, the incident cases of colorectal cancer were found as 40.1 per 100,000 people per year.

The increasing geriatric population is mostly frail and unable to tolerate the treatments such as radiation therapy and chemotherapy for the treatment of cancer. This is one of the most prominent factor due to which companies are focusing towards development of therapeutics for the treatment of rectal cancer.

Key Players

  • Taiwan Liposome Company
  • Sanofi
  • Advaxis Inc.

Other Notable Players

  • Eli Lilly & Co

Key Topics Covered

1. Research Background

2. Research Methodology

3. Executive Summary

4. Pipeline Outlook

5. Rectal Cancer Therapeutics Pipeline Analysis by Phase (2018)

6. Clinical Trials Review

7. Competitive Landscape

8. Company Profiles

For more information about this report visit https://www.researchandmarkets.com/research/s4clg9/rectal_cancer?w=4

Contacts

ResearchAndMarkets.com
Laura Wood, Senior Manager
press@researchandmarkets.com
For E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
Related Topics: Colon Cancer Drugs , Clinical Trials

Contacts

ResearchAndMarkets.com
Laura Wood, Senior Manager
press@researchandmarkets.com
For E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
Related Topics: Colon Cancer Drugs , Clinical Trials